MX2009009693A - Metodos para activar irs-1 y akt. - Google Patents
Metodos para activar irs-1 y akt.Info
- Publication number
- MX2009009693A MX2009009693A MX2009009693A MX2009009693A MX2009009693A MX 2009009693 A MX2009009693 A MX 2009009693A MX 2009009693 A MX2009009693 A MX 2009009693A MX 2009009693 A MX2009009693 A MX 2009009693A MX 2009009693 A MX2009009693 A MX 2009009693A
- Authority
- MX
- Mexico
- Prior art keywords
- akt
- methods
- irs
- activating
- activating irs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona los métodos para activar IRS-1 y/o AKT y los métodos para tratar o prevenir una enfermedad, afección o trastorno relacionado a IRS-1 y/o AKT.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95130907P | 2007-07-23 | 2007-07-23 | |
PCT/US2008/070739 WO2009015133A1 (en) | 2007-07-23 | 2008-07-22 | Methods of activating irs-1 and akt |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009009693A true MX2009009693A (es) | 2009-10-07 |
Family
ID=40281761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009693A MX2009009693A (es) | 2007-07-23 | 2008-07-22 | Metodos para activar irs-1 y akt. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20100197710A1 (es) |
EP (1) | EP2180894A4 (es) |
JP (1) | JP2010534668A (es) |
CN (1) | CN101668530A (es) |
AU (1) | AU2008279242A1 (es) |
BR (1) | BRPI0813167A2 (es) |
CA (1) | CA2693809A1 (es) |
IL (1) | IL200541A0 (es) |
MX (1) | MX2009009693A (es) |
NZ (1) | NZ579288A (es) |
WO (1) | WO2009015133A1 (es) |
ZA (1) | ZA200906782B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5113752B2 (ja) | 2005-08-22 | 2013-01-09 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Lynキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤 |
US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
CN103764830A (zh) * | 2011-06-30 | 2014-04-30 | 基因信号国际公司 | 含有irs-1抑制剂和vegf抑制剂的组合物 |
RU2646475C2 (ru) | 2011-12-12 | 2018-03-05 | МЕЛИОР ФАРМАСЬЮТИКАЛЗ Ай, ИНК. | Лечение диабета I и II типа |
CN110785170B (zh) | 2017-04-10 | 2023-03-28 | 梅里奥尔医药I公司 | 脂肪细胞的治疗 |
US20220031700A1 (en) * | 2020-07-30 | 2022-02-03 | Melior Pharmaceuticals I, Inc. | Treatment of Acute Respiratory Distress Syndrome (ARDS) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3922345A (en) * | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
US4080454A (en) * | 1976-07-16 | 1978-03-21 | Pfizer Inc. | 5-M-Tolyloxyuracil, anti-ulcer agent |
US4612376A (en) * | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
US5698155A (en) * | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
US20020019346A1 (en) * | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
US6037323A (en) * | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
ES2290743T3 (es) * | 2003-04-30 | 2008-02-16 | The Institutes For Pharmaceutical Discovery, Llc | Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas. |
US20060035302A1 (en) * | 2004-06-21 | 2006-02-16 | Applera Corporation | Kinase substrates with multiple phosphorylation sites |
EP1827434B1 (en) * | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
JP5113752B2 (ja) * | 2005-08-22 | 2013-01-09 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Lynキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤 |
EP1924264B9 (en) * | 2005-09-01 | 2014-02-19 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
-
2008
- 2008-07-22 BR BRPI0813167-8A2A patent/BRPI0813167A2/pt not_active Application Discontinuation
- 2008-07-22 JP JP2010518330A patent/JP2010534668A/ja active Pending
- 2008-07-22 US US12/669,574 patent/US20100197710A1/en not_active Abandoned
- 2008-07-22 NZ NZ579288A patent/NZ579288A/en not_active IP Right Cessation
- 2008-07-22 MX MX2009009693A patent/MX2009009693A/es unknown
- 2008-07-22 AU AU2008279242A patent/AU2008279242A1/en not_active Abandoned
- 2008-07-22 CN CN200880013253A patent/CN101668530A/zh active Pending
- 2008-07-22 EP EP08796414A patent/EP2180894A4/en not_active Withdrawn
- 2008-07-22 WO PCT/US2008/070739 patent/WO2009015133A1/en active Application Filing
- 2008-07-22 CA CA2693809A patent/CA2693809A1/en not_active Abandoned
-
2009
- 2009-08-20 IL IL200541A patent/IL200541A0/en unknown
- 2009-09-29 ZA ZA200906782A patent/ZA200906782B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2693809A1 (en) | 2009-01-29 |
CN101668530A (zh) | 2010-03-10 |
IL200541A0 (en) | 2010-04-29 |
WO2009015133A1 (en) | 2009-01-29 |
NZ579288A (en) | 2012-06-29 |
BRPI0813167A2 (pt) | 2014-12-23 |
ZA200906782B (en) | 2010-07-28 |
EP2180894A4 (en) | 2012-08-29 |
JP2010534668A (ja) | 2010-11-11 |
AU2008279242A1 (en) | 2009-01-29 |
US20100197710A1 (en) | 2010-08-05 |
EP2180894A1 (en) | 2010-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
MY161495A (en) | Virus like particle compositions and methods of use | |
MX2009012625A (es) | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. | |
WO2009108860A3 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
MY173616A (en) | Compositions and methods for lowering triglycerides | |
WO2008094708A3 (en) | Activin-actriia antagonists and uses for treating or preventing breast cancer | |
UA98629C2 (ru) | Соединения и способ модуляции киназ | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
MY172151A (en) | Certain chemical entities, compositions and methods | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
TNSN08400A1 (en) | Organic compounds and their uses | |
WO2008091692A3 (en) | Methods of diagnosing, treating, and preventing increased vascular permeability | |
MX2010006823A (es) | Metodos para el tratamiento de la gota. | |
TN2010000096A1 (en) | Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors | |
WO2009044173A3 (en) | Methods of treating cancer using notch pathway inhibitors | |
MY159491A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
MX2009009693A (es) | Metodos para activar irs-1 y akt. | |
WO2009158374A3 (en) | Inhibitors of akt activity | |
TN2011000166A1 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
WO2009009034A3 (en) | Methods and compositions useful in the treatment of mucositis | |
TNSN08496A1 (en) | Aminothiazoles and their uses | |
MX2010010393A (es) | Uso de la catepsina c. |